Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Penumbra Inc. (PEN:NYSE), powered by AI.
Penumbra Inc. is currently trading at $318.46. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Penumbra Inc. on Alpha Lenz.
Penumbra Inc.'s P/E ratio is 69.8.
“Penumbra Inc. trades at a P/E of 69.8 (premium valuation) with solid ROE of 13.8%. 3Y revenue CAGR of 18.3% highlights clear growth momentum.”
Ask for details →Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
“Penumbra Inc. trades at a P/E of 69.8 (premium valuation) with solid ROE of 13.8%. 3Y revenue CAGR of 18.3% highlights clear growth momentum.”
Ask for details →Penumbra Inc. (ticker: PEN) is a company listed on NYSE in the Healthcare sector (Medical Devices). It has approximately 4,500 employees. Market cap is $12.4B.
The current price is $318.46 with a P/E ratio of 69.75x and P/B of 8.68x.
ROE is 13.78% and operating margin is 13.48%. Annual revenue is $1.4B.